Aytu biopharma reports record adhd revenue and operating income during fiscal 2024 second quarter

Q2 2024 operating income of $2.4 million q2 2024 net loss of $0.2 million and adjusted ebitda1 of $5.1 million q2 2024 rx segment net revenue of $18.7 million, net income of $0.7 million, and adjusted ebitda of $5.5 million q2 2024 adhd portfolio net revenue up 49% compared to q2 2023 $19.5 million cash balance at december 31, 2023 company to host conference call and webcast today, february 14, 2024 at 4:30 p.m. eastern time denver, co / accesswire / february 14, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
AYTU Ratings Summary
AYTU Quant Ranking